Impact of apolipoprotein A5 variants on statin treatment efficacy (Q28248690)

Michaela Snejdrlova

4

0 references

Katerina Hirschfeldova

Katerina Hirschfeldova

5

0 references

Michal Vrablík

Michal Vrablik

8

0 references

Richard Češka

Richard Ceska

7

0 references

author name string

Jaroslav A Hubacek

1

0 references

Vera Adamkova

2

0 references

Martina Prusikova

3

0 references

Vera Lanska

The forgotten majority: unfinished business in cardiovascular risk reduction

6

0 references

language of work or name

English

0 references

publication date

June 2009

0 references

published in

Pharmacogenomics

0 references

volume

10

0 references

issue

6

0 references

page(s)

945-50

0 references

cites work

1 reference

Pharmacogenomics of cholesterol-lowering therapy

21 January 2018

1 reference

An apolipoprotein influencing triglycerides in humans and mice revealed by comparative sequencing

21 January 2018

1 reference

Influence of the APOA5 locus on plasma triglyceride, lipoprotein subclasses, and CVD risk in the Framingham Heart Study

21 January 2018

1 reference

Apolipoprotein A5 and triglyceridemia. Focus on the effects of the common variants

21 January 2018

1 reference

APOA5 and triglyceride metabolism, lesson from human APOA5 deficiency

21 January 2018

1 reference

The influence of APOAV polymorphisms (T-1131>C and S19>W) on plasma triglyceride levels and risk of myocardial infarction

21 January 2018

1 reference

Polymorphism in the promoter region of the apolipoprotein A5 gene is associated with an increased susceptibility for coronary artery disease.

21 January 2018

1 reference

Clinical significance of apolipoprotein A5

21 January 2018

1 reference

Effects of six APOA5 variants, identified in patients with severe hypertriglyceridemia, on in vitro lipoprotein lipase activity and receptor binding

21 January 2018

1 reference

APOA5 variant Ser19Trp influences a decrease of the total cholesterol in a male 8 year cohort

21 January 2018

1 reference

Polymorphisms in the APOA1/C3/A4/A5 gene cluster and cholesterol responsiveness to dietary change

21 January 2018

1 reference

Dietary intake of n-6 fatty acids modulates effect of apolipoprotein A5 gene on plasma fasting triglycerides, remnant lipoprotein concentrations, and lipoprotein particle size: the Framingham Heart Study

21 January 2018

1 reference

Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study.

21 January 2018

1 reference

Sex-specific effect of APOAV variant (Val153>Met) on plasma levels of high-density lipoprotein cholesterol

21 January 2018

1 reference

The apolipoprotein A-V genotype and plasma apolipoprotein A-V and triglyceride levels: prospective risk of type 2 diabetes. Results from the Northwick Park Heart Study II.

21 January 2018

1 reference

The novel apolipoprotein A5 is present in human serum, is associated with VLDL, HDL, and chylomicrons, and circulates at very low concentrations compared with other apolipoproteins

21 January 2018

1 reference

Pharmacogenetics of apolipoprotein E gene during lipid-lowering therapy: lipid levels and prevention of coronary heart disease

21 January 2018

1 reference

Genes mirror geography within Europe

21 January 2018

1 reference

Plasma apolipoprotein A5 and triglycerides in type 2 diabetes

21 January 2018

1 reference